A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies

Elena Santagostino, Guy Young, Manuel Carcao, Pier Mannuccio Mannucci, Susan Halimeh, Steve Austin

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: The development of inhibitors against factor VIII (FVIII) replacement therapy remains the most important challenge for clinicians in the treatment of hemophilia patients. This review focusses on risk factors and management of FVIII inhibitors, particularly in light of SIPPET study findings and subsequent analyses. Areas covered: A brief history and evolution of hemophilia therapies is provided, including an overview of conventional and new (including investigational) therapeutic approaches for the treatment of hemophilia. The SIPPET study, the first randomized clinical trial to demonstrate a lower incidence of inhibitors in previously untreated patients treated with plasma-derived FVIII products compared with recombinant FVIII products, has generated much debate. We review the SIPPET trial and reactions, in addition to preliminary observations from a single center’s experience, the cost impact of inhibitors, recent findings from SIPPET subanalyses, and inhibitor development in previously-treated patients. Expert commentary: Despite recent advances in potential new treatment options for hemophilia, conventional factor replacement concentrates currently remain the cornerstone of treatment. It is paramount that clinicians familiarize themselves with the findings from the SIPPET trial and substudies, in order to better inform their patients and families on inhibitor risk factors and to aid the treatment decision-making process.

Original languageEnglish
Pages (from-to)87-97
Number of pages11
JournalExpert Review of Hematology
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Factor VIII
Hemophilia A
Therapeutics
Risk Management
Decision Making
Randomized Controlled Trials
History
Costs and Cost Analysis
Incidence

Keywords

  • Factor VIII
  • hemophilia
  • inhibitors
  • plasma-derived FVIII
  • recombinant FVIII
  • SIPPET

ASJC Scopus subject areas

  • Hematology

Cite this

A contemporary look at FVIII inhibitor development : still a great influence on the evolution of hemophilia therapies. / Santagostino, Elena; Young, Guy; Carcao, Manuel; Mannucci, Pier Mannuccio; Halimeh, Susan; Austin, Steve.

In: Expert Review of Hematology, Vol. 11, No. 2, 01.02.2018, p. 87-97.

Research output: Contribution to journalReview article

@article{12966f9640204d74af9e0982cf26ce63,
title = "A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies",
abstract = "Introduction: The development of inhibitors against factor VIII (FVIII) replacement therapy remains the most important challenge for clinicians in the treatment of hemophilia patients. This review focusses on risk factors and management of FVIII inhibitors, particularly in light of SIPPET study findings and subsequent analyses. Areas covered: A brief history and evolution of hemophilia therapies is provided, including an overview of conventional and new (including investigational) therapeutic approaches for the treatment of hemophilia. The SIPPET study, the first randomized clinical trial to demonstrate a lower incidence of inhibitors in previously untreated patients treated with plasma-derived FVIII products compared with recombinant FVIII products, has generated much debate. We review the SIPPET trial and reactions, in addition to preliminary observations from a single center’s experience, the cost impact of inhibitors, recent findings from SIPPET subanalyses, and inhibitor development in previously-treated patients. Expert commentary: Despite recent advances in potential new treatment options for hemophilia, conventional factor replacement concentrates currently remain the cornerstone of treatment. It is paramount that clinicians familiarize themselves with the findings from the SIPPET trial and substudies, in order to better inform their patients and families on inhibitor risk factors and to aid the treatment decision-making process.",
keywords = "Factor VIII, hemophilia, inhibitors, plasma-derived FVIII, recombinant FVIII, SIPPET",
author = "Elena Santagostino and Guy Young and Manuel Carcao and Mannucci, {Pier Mannuccio} and Susan Halimeh and Steve Austin",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/17474086.2018.1419862",
language = "English",
volume = "11",
pages = "87--97",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - A contemporary look at FVIII inhibitor development

T2 - still a great influence on the evolution of hemophilia therapies

AU - Santagostino, Elena

AU - Young, Guy

AU - Carcao, Manuel

AU - Mannucci, Pier Mannuccio

AU - Halimeh, Susan

AU - Austin, Steve

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: The development of inhibitors against factor VIII (FVIII) replacement therapy remains the most important challenge for clinicians in the treatment of hemophilia patients. This review focusses on risk factors and management of FVIII inhibitors, particularly in light of SIPPET study findings and subsequent analyses. Areas covered: A brief history and evolution of hemophilia therapies is provided, including an overview of conventional and new (including investigational) therapeutic approaches for the treatment of hemophilia. The SIPPET study, the first randomized clinical trial to demonstrate a lower incidence of inhibitors in previously untreated patients treated with plasma-derived FVIII products compared with recombinant FVIII products, has generated much debate. We review the SIPPET trial and reactions, in addition to preliminary observations from a single center’s experience, the cost impact of inhibitors, recent findings from SIPPET subanalyses, and inhibitor development in previously-treated patients. Expert commentary: Despite recent advances in potential new treatment options for hemophilia, conventional factor replacement concentrates currently remain the cornerstone of treatment. It is paramount that clinicians familiarize themselves with the findings from the SIPPET trial and substudies, in order to better inform their patients and families on inhibitor risk factors and to aid the treatment decision-making process.

AB - Introduction: The development of inhibitors against factor VIII (FVIII) replacement therapy remains the most important challenge for clinicians in the treatment of hemophilia patients. This review focusses on risk factors and management of FVIII inhibitors, particularly in light of SIPPET study findings and subsequent analyses. Areas covered: A brief history and evolution of hemophilia therapies is provided, including an overview of conventional and new (including investigational) therapeutic approaches for the treatment of hemophilia. The SIPPET study, the first randomized clinical trial to demonstrate a lower incidence of inhibitors in previously untreated patients treated with plasma-derived FVIII products compared with recombinant FVIII products, has generated much debate. We review the SIPPET trial and reactions, in addition to preliminary observations from a single center’s experience, the cost impact of inhibitors, recent findings from SIPPET subanalyses, and inhibitor development in previously-treated patients. Expert commentary: Despite recent advances in potential new treatment options for hemophilia, conventional factor replacement concentrates currently remain the cornerstone of treatment. It is paramount that clinicians familiarize themselves with the findings from the SIPPET trial and substudies, in order to better inform their patients and families on inhibitor risk factors and to aid the treatment decision-making process.

KW - Factor VIII

KW - hemophilia

KW - inhibitors

KW - plasma-derived FVIII

KW - recombinant FVIII

KW - SIPPET

UR - http://www.scopus.com/inward/record.url?scp=85041200904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041200904&partnerID=8YFLogxK

U2 - 10.1080/17474086.2018.1419862

DO - 10.1080/17474086.2018.1419862

M3 - Review article

AN - SCOPUS:85041200904

VL - 11

SP - 87

EP - 97

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -